A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study

Bictegravir (BIC), a newly FDA-approved integrase strand transfer inhibitor (INSTI), as a single tablet regimen has proven efficacious in treating HIV-1 and SIV viruses, with reduced resistance. BIC clinical trials have not investigated its prophylaxis potency. This study investigates the HIV preven...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2019-07, Vol.167, p.83-88
Main Authors: Mandal, Subhra, Prathipati, Pavan Kumar, Belshan, Michael, Destache, Christopher J.
Format: Article
Language:English
Subjects:
Antiretroviral therapy
Bictegravir
Cell Line
Drug Delivery Systems - methods
Heterocyclic Compounds, 4 or More Rings - pharmacokinetics
Heterocyclic Compounds, 4 or More Rings - toxicity
HIV Infections - drug therapy
HIV-1 - drug effects
HIV-1 prophylaxis
Humans
Inhibitory Concentration 50
Nanoparticles
Nanoparticles - therapeutic use
Nanoparticles - virology
Proof of Concept Study
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bictegravir (BIC), a newly FDA-approved integrase strand transfer inhibitor (INSTI), as a single tablet regimen has proven efficacious in treating HIV-1 and SIV viruses, with reduced resistance. BIC clinical trials have not investigated its prophylaxis potency. This study investigates the HIV prevention potency of a novel long-acting BIC nano-formulation aimed to improve adherence. Poly (lactic-co-glycolic acid) loaded BIC nanoparticles (BIC NPs) were formulated using an oil-in-water emulsion methodology. BIC NPs were
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2019.04.007